Blood biomarkers for evaluation of perinatal encephalopathy: State of the art

Research output: Contribution to journalReview article

Abstract

Purpose of review The rapid progress in biomarker science is on the threshold of significantly changing clinical care for infants in the neonatal ICU. Infants with neonatal brain injuries will likely be the first group whose management is dramatically altered with point-of-care, rapidly available brain biomarker analysis. Providing an interim update on progress in this area is the purpose of this review. Recent findings Highlighted findings from the past 18 months of publications on biomarkers in neonatal brain injury include; Specific nonbrain markers of cardiac health and global asphyxia continue to provide information on brain injury after hypoxic-ischemic encephalopathy (HIE). Prediction of injury in the piglet hypoxia-ischemia model is improved with the use of a combination score of plasma metabolites. In a neonatal piglet model of perinatal hypoxia-ischemia, a systemic proinflammatory surge of cytokines has been identified after rewarming from therapeutic hypothermia. New biomarkers identified recently include osteopontin, activin A, neutrophil gelatinase-associated lipocalin, secretoneurin, Tau and neurofilament light protein. Brain-based biomarkers differ in their ability to predict short-term in-hospital outcomes and long-term neurologic deficits. Summary Neonatal brain biomarker research is currently in its very early development with major advances still to be made.

Original languageEnglish (US)
Pages (from-to)199-203
Number of pages5
JournalCurrent Opinion in Pediatrics
Volume30
Issue number2
DOIs
StatePublished - Apr 1 2018

Fingerprint

Brain Diseases
Biomarkers
Brain Injuries
Brain
Ischemia
Point-of-Care Systems
Infant Care
Brain Hypoxia-Ischemia
Induced Hypothermia
Rewarming
Osteopontin
Asphyxia
Neonatal Intensive Care Units
Neurologic Manifestations
Publications
Cytokines
Wounds and Injuries
Research

Keywords

  • cytokines
  • digital ELISA
  • metabolites
  • neonatal brain injury
  • outcomes

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Blood biomarkers for evaluation of perinatal encephalopathy : State of the art. / Graham, Ernest M; Everett, Allen D; Delpech, Jean Christophe; Northington, Frances.

In: Current Opinion in Pediatrics, Vol. 30, No. 2, 01.04.2018, p. 199-203.

Research output: Contribution to journalReview article

@article{9e220046acb6455199b61866a7495ad7,
title = "Blood biomarkers for evaluation of perinatal encephalopathy: State of the art",
abstract = "Purpose of review The rapid progress in biomarker science is on the threshold of significantly changing clinical care for infants in the neonatal ICU. Infants with neonatal brain injuries will likely be the first group whose management is dramatically altered with point-of-care, rapidly available brain biomarker analysis. Providing an interim update on progress in this area is the purpose of this review. Recent findings Highlighted findings from the past 18 months of publications on biomarkers in neonatal brain injury include; Specific nonbrain markers of cardiac health and global asphyxia continue to provide information on brain injury after hypoxic-ischemic encephalopathy (HIE). Prediction of injury in the piglet hypoxia-ischemia model is improved with the use of a combination score of plasma metabolites. In a neonatal piglet model of perinatal hypoxia-ischemia, a systemic proinflammatory surge of cytokines has been identified after rewarming from therapeutic hypothermia. New biomarkers identified recently include osteopontin, activin A, neutrophil gelatinase-associated lipocalin, secretoneurin, Tau and neurofilament light protein. Brain-based biomarkers differ in their ability to predict short-term in-hospital outcomes and long-term neurologic deficits. Summary Neonatal brain biomarker research is currently in its very early development with major advances still to be made.",
keywords = "cytokines, digital ELISA, metabolites, neonatal brain injury, outcomes",
author = "Graham, {Ernest M} and Everett, {Allen D} and Delpech, {Jean Christophe} and Frances Northington",
year = "2018",
month = "4",
day = "1",
doi = "10.1097/MOP.0000000000000591",
language = "English (US)",
volume = "30",
pages = "199--203",
journal = "Current Opinion in Pediatrics",
issn = "1040-8703",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Blood biomarkers for evaluation of perinatal encephalopathy

T2 - State of the art

AU - Graham, Ernest M

AU - Everett, Allen D

AU - Delpech, Jean Christophe

AU - Northington, Frances

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Purpose of review The rapid progress in biomarker science is on the threshold of significantly changing clinical care for infants in the neonatal ICU. Infants with neonatal brain injuries will likely be the first group whose management is dramatically altered with point-of-care, rapidly available brain biomarker analysis. Providing an interim update on progress in this area is the purpose of this review. Recent findings Highlighted findings from the past 18 months of publications on biomarkers in neonatal brain injury include; Specific nonbrain markers of cardiac health and global asphyxia continue to provide information on brain injury after hypoxic-ischemic encephalopathy (HIE). Prediction of injury in the piglet hypoxia-ischemia model is improved with the use of a combination score of plasma metabolites. In a neonatal piglet model of perinatal hypoxia-ischemia, a systemic proinflammatory surge of cytokines has been identified after rewarming from therapeutic hypothermia. New biomarkers identified recently include osteopontin, activin A, neutrophil gelatinase-associated lipocalin, secretoneurin, Tau and neurofilament light protein. Brain-based biomarkers differ in their ability to predict short-term in-hospital outcomes and long-term neurologic deficits. Summary Neonatal brain biomarker research is currently in its very early development with major advances still to be made.

AB - Purpose of review The rapid progress in biomarker science is on the threshold of significantly changing clinical care for infants in the neonatal ICU. Infants with neonatal brain injuries will likely be the first group whose management is dramatically altered with point-of-care, rapidly available brain biomarker analysis. Providing an interim update on progress in this area is the purpose of this review. Recent findings Highlighted findings from the past 18 months of publications on biomarkers in neonatal brain injury include; Specific nonbrain markers of cardiac health and global asphyxia continue to provide information on brain injury after hypoxic-ischemic encephalopathy (HIE). Prediction of injury in the piglet hypoxia-ischemia model is improved with the use of a combination score of plasma metabolites. In a neonatal piglet model of perinatal hypoxia-ischemia, a systemic proinflammatory surge of cytokines has been identified after rewarming from therapeutic hypothermia. New biomarkers identified recently include osteopontin, activin A, neutrophil gelatinase-associated lipocalin, secretoneurin, Tau and neurofilament light protein. Brain-based biomarkers differ in their ability to predict short-term in-hospital outcomes and long-term neurologic deficits. Summary Neonatal brain biomarker research is currently in its very early development with major advances still to be made.

KW - cytokines

KW - digital ELISA

KW - metabolites

KW - neonatal brain injury

KW - outcomes

UR - http://www.scopus.com/inward/record.url?scp=85044187415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044187415&partnerID=8YFLogxK

U2 - 10.1097/MOP.0000000000000591

DO - 10.1097/MOP.0000000000000591

M3 - Review article

C2 - 29346139

AN - SCOPUS:85044187415

VL - 30

SP - 199

EP - 203

JO - Current Opinion in Pediatrics

JF - Current Opinion in Pediatrics

SN - 1040-8703

IS - 2

ER -